Mark Zimmerman Email

SVP Business Development and Operations . ViaCyte

Current Roles

Employees:
56
Revenue:
$4.3M
About
ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments that will reduce or eliminate the need for blood glucose monitoring, insulin administration, and the risks of hypoglycemia and diabetes-related complications. ViaCyte has two products in clinical development. The first is called the PEC-Direct product candidate, which delivers proprietary pancreatic progenitor cells (PEC-01 cells) in a non-immunoprotective device. The PEC-Direct product candidate is being developed for type 1 diabetes (T1D) patients who have hypoglycemia unawareness, recurrent severe hypoglycemic episodes, and/or extreme glycemic lability.  The second product is called the PEC-Encap (also known as VC-01) product candidate. The PEC-Encap product candidate delivers pancreatic progenitor cells in an immunoprotective device and is being developed as a potential therapy for all diabetes patients who use insulin to control their disease. www.viacyte.com
ViaCyte Address
3550 General Atomics Court
San Diego, CA
United States
ViaCyte Email

Past Companies

FreelanceConsultant
ViaCyteSenior Vice President of Business Development and Operations
ViacyteVice President - Business Development and Interim Operations Leader

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.